Vaccination plus previous infection: protection during the omicron wave in Brazil.
作者信息
Cerqueira-Silva Thiago, de Araujo Oliveira Vinicius, Paixão Enny S, Florentino Pilar Tavares Veras, Penna Gerson O, Pearce Neil, Werneck Guilherme L, Barreto Maurício L, Boaventura Viviane S, Barral-Netto Manoel
机构信息
LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil; Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Universidade Federal da Bahia, Salvador, Bahia, Brazil; Center of Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia 40296-710, Brazil.
出版信息
Lancet Infect Dis. 2022 Jul;22(7):945-946. doi: 10.1016/S1473-3099(22)00288-2. Epub 2022 May 16.
Abstract
摘要
相似文献
1
Vaccination plus previous infection: protection during the omicron wave in Brazil.疫苗接种加既往感染：巴西奥密克戎毒株流行期间的保护作用
Lancet Infect Dis. 2022 Jul;22(7):945-946. doi: 10.1016/S1473-3099(22)00288-2. Epub 2022 May 16.
2
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.古巴2至11岁儿童在新冠病毒奥密克戎毒株流行期间采用异源SOBERANA-02和SOBERANA-Plus疫苗接种方案的真实世界有效性：一项纵向病例群体研究
Lancet Reg Health Am. 2024 Apr 23;34:100750. doi: 10.1016/j.lana.2024.100750. eCollection 2024 Jun.
3
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.2021 年 8 月至 2022 年 3 月，英国青少年在先前感染和接种疫苗后对 delta（B.1.617.2）和 omicron（B.1.1.529）BA.1 和 BA.2 SARS-CoV-2 变异株的症状性感染的保护作用：一项全国性、观察性、基于检测的病例对照研究。
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.
4
Indirect effectiveness of COVID-19 vaccines in the pre-omicron and omicron periods: A nation-wide test-negative case-control study in Brazil.COVID-19 疫苗在奥密克戎前和奥密克戎时期的间接效果：巴西全国性的病例对照研究。
Int J Infect Dis. 2024 Nov;148:107241. doi: 10.1016/j.ijid.2024.107241. Epub 2024 Sep 18.
5
Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.mRNA 加强针在巴西和苏格兰使用 BNT162b2 或 ChAdOx1 进行同源初级系列接种后对有症状感染和严重 COVID-19 的有效性：一项基于病例对照设计的检测阴性研究。
PLoS Med. 2023 Jan 11;20(1):e1004156. doi: 10.1371/journal.pmed.1004156. eCollection 2023 Jan.
6
Protection against Omicron from Vaccination and Previous Infection in a Prison System.监狱系统中疫苗接种和既往感染对奥密克戎的保护作用。
N Engl J Med. 2022 Nov 10;387(19):1770-1782. doi: 10.1056/NEJMoa2207082. Epub 2022 Oct 26.
7
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.新加坡一项全国性队列研究：SARS-CoV-2 感染和疫苗对有医疗记录的奥密克戎 BA.4、BA.5 和 XBB 再感染相关症状的保护免疫作用。
Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9. Epub 2023 Mar 13.
8
Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.保护 COVID-19 疫苗接种和既往感染对奥密克戎 BA.1、BA.2 和德尔塔 SARS-CoV-2 感染的作用。
Nat Commun. 2022 Aug 12;13(1):4738. doi: 10.1038/s41467-022-31838-8.
9
Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study.先前严重急性呼吸综合征冠状病毒 2 感染提供的针对奥密克戎变异株的保护作用：一项回顾性队列研究。
Clin Infect Dis. 2023 Feb 8;76(3):e142-e147. doi: 10.1093/cid/ciac604.
10
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil.科兴疫苗加强针与辉瑞-BioNTech 异源疫苗对奥密克戎变异株的保护效力持续时间：巴西研究
Nat Commun. 2022 Jul 18;13(1):4154. doi: 10.1038/s41467-022-31839-7.
引用本文的文献
1
Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review.一剂新冠病毒mRNA疫苗对既往感染过严重急性呼吸综合征冠状病毒2的个体的有效性：一项系统评价
Commun Med (Lond). 2025 May 3;5(1):151. doi: 10.1038/s43856-025-00882-y.
2
Characteristics and risk factors associated with COVID-19 reinfection in Hong Kong: a retrospective cohort study.香港新冠病毒再感染的特征及相关风险因素：一项回顾性队列研究。
Epidemiol Infect. 2025 Feb 7;153:e30. doi: 10.1017/S0950268825000172.
3
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.在南非，接受SARS-CoV-2重组刺突蛋白疫苗（NVX-CoV2373）与含Matrix-M佐剂的同源加强剂量接种后的免疫原性和安全性，与HIV-1感染和未感染人群的初始系列接种情况对比：一项随机交叉2a/2b期试验
Hum Vaccin Immunother. 2024 Dec 31;20(1):2425147. doi: 10.1080/21645515.2024.2425147. Epub 2024 Dec 12.
4
Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.奥密克戎变异株再感染风险的混合免疫元分析。
Front Public Health. 2024 Aug 26;12:1457266. doi: 10.3389/fpubh.2024.1457266. eCollection 2024.
5
COVID-19 Vaccine Uptake and Effectiveness by Time since Vaccination in the Western Cape Province, South Africa: An Observational Cohort Study during 2020-2022.南非西开普省自接种疫苗后的时间来看新冠疫苗的接种率及有效性：一项2020 - 2022年的观察性队列研究
Vaccines (Basel). 2024 Jun 5;12(6):628. doi: 10.3390/vaccines12060628.
6
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination.针对新冠病毒奥密克戎变种的中和抗体水平下降可通过混合免疫和原始/奥密克戎二价疫苗接种得到增强。
Vaccines (Basel). 2024 May 22;12(6):564. doi: 10.3390/vaccines12060564.
7
Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada.先前 SARS-CoV-2 感染、COVID-19 加强针和混合免疫对奥密克戎重症的保护作用：加拿大五百万居民的基于人群的队列研究。
PLoS One. 2024 Feb 23;19(2):e0299304. doi: 10.1371/journal.pone.0299304. eCollection 2024.
8
Counterfactual analysis of the 2023 Omicron XBB wave in China.对中国2023年奥密克戎XBB毒株浪潮的反事实分析。
Infect Dis Model. 2024 Jan 8;9(1):195-203. doi: 10.1016/j.idm.2023.12.006. eCollection 2024 Mar.
9
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination.接种疫苗后新冠病毒突破性感染的预测因素
Vaccines (Basel). 2023 Dec 28;12(1):36. doi: 10.3390/vaccines12010036.
10
Impact of Vaccination and Nonpharmaceutical Interventions With Possible COVID-19 Viral Evolutions Using an Agent-Based Simulation.基于主体模拟的疫苗接种和非药物干预对可能的新冠病毒进化的影响
AJPM Focus. 2023 Oct 10;3(1):100155. doi: 10.1016/j.focus.2023.100155. eCollection 2024 Feb.
本文引用的文献
1
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study.新冠病毒疫苗对奥密克戎和德尔塔毒株导致住院治疗的有效性：一项检测呈阴性的病例对照研究
Nat Commun. 2022 Sep 30;13(1):5736. doi: 10.1038/s41467-022-33378-7.
2
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.在巴西，既往感染过 SARS-CoV-2 的个体中 CoronaVac、ChAdOx1 nCoV-19、BNT162b2 和 Ad26.COV2.S 的有效性：一项病例对照研究。
Lancet Infect Dis. 2022 Jun;22(6):791-801. doi: 10.1016/S1473-3099(22)00140-2. Epub 2022 Apr 1.
3
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
Zotero 插件